Literature DB >> 1913298

Skeletal size and bone mineral content in Turner's syndrome: relation to karyotype, estrogen treatment, physical fitness, and bone turnover.

R W Naeraa1, K Brixen, R M Hansen, C Hasling, L Mosekilde, J H Andresen, P Charles, J Nielsen.   

Abstract

Bone mineral content (BMC), bone mineral density, and metacarpal dimensions were studied in 50 women with Turner's syndrome aged 21-45 years in relation to karyotype, estrogen treatment, physical fitness, and biochemical markers of bone turnover. No differences were found between the 25 women with karyotype 45.X and women with other karyotypes. Forty-six women had received estrogen. Significant partial correlations were found between bone mineral density of the forearm and duration of estrogen treatment and physical fitness. BMC of the lumbar spine corrected for vertebral height (BMC(C)spine) was directly correlated with duration of estrogen treatment and height, marginally correlated with physical fitness, and inversely correlated with age. Outer metacarpal width was positively correlated with duration of estrogen treatment, age at initiation of therapy, and body weight. The diameter of medullary space showed negative correlation with physical fitness and height, and positive correlation with age at initiation of estrogen treatment. Cortical thickness was positively correlated with duration of estrogen treatment, physical fitness, and height. No convincing effects of estrogen could be demonstrated in women below the age of 30. Above the age of 30, all bone mineral measurements were markedly elevated in women treated for longer than the average of this age group. BMC(C)spine was inversely correlated with biochemical markers of bone formation. Our results demonstrate that estrogen treatment and physical fitness are important determinants of bone mineral status in Turner's syndrome and add to the evidence that estrogen treatment increases BMC in Turner's syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913298     DOI: 10.1007/bf02565125

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  47 in total

1.  A sex-chromosome anomaly in a case of gonadal dysgenesis (Turner's syndrome).

Authors:  C E FORD; K W JONES; P E POLANI; J C DE ALMEIDA; J H BRIGGS
Journal:  Lancet       Date:  1959-04-04       Impact factor: 79.321

2.  The interaction of growth hormone, somatomedin and oestrogen in patients with Turner's syndrome.

Authors:  P Saenger; E Schwartz; E Wiedemann; L S Levine; M Tsai; M I New
Journal:  Acta Endocrinol (Copenh)       Date:  1976-01

3.  Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells.

Authors:  B S Komm; C M Terpening; D J Benz; K A Graeme; A Gallegos; M Korc; G L Greene; B W O'Malley; M R Haussler
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

4.  Osteoporosis in ovarian dysgenesis.

Authors:  D M Brown; J Jowsey; D S Bradford
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

5.  Orthopedic aspects of the XO (Turner's) syndrome.

Authors:  R K Beals
Journal:  Clin Orthop Relat Res       Date:  1973 Nov-Dec       Impact factor: 4.176

6.  Turner syndrome: spontaneous growth in 150 cases and review of the literature.

Authors:  M B Ranke; H Pflüger; W Rosendahl; P Stubbe; H Enders; J R Bierich; F Majewski
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

7.  Comparison of pharmacodynamic properties of various estrogen formulations.

Authors:  C A Mashchak; R A Lobo; R Dozono-Takano; P Eggena; R M Nakamura; P F Brenner; D R Mishell
Journal:  Am J Obstet Gynecol       Date:  1982-11-01       Impact factor: 8.661

8.  Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma.

Authors:  S B Rosalki; A Y Foo
Journal:  Clin Chem       Date:  1984-07       Impact factor: 8.327

9.  Some effects of basic multicellular unit-based remodelling on photon absorptiometry of trabecular bone.

Authors:  H M Frost
Journal:  Bone Miner       Date:  1989-08

10.  Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility.

Authors:  W Behr; J Barnert
Journal:  Clin Chem       Date:  1986-10       Impact factor: 8.327

View more
  6 in total

1.  Association between ER-α polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment--a pilot study.

Authors:  Elżbieta Sowińska-Przepiera; Elżbieta Andrysiak-Mamos; Kornel Chełstowski; Grażyna Adler; Zbigniew Friebe; Anhelli Syrenicz
Journal:  J Bone Miner Metab       Date:  2011-01-27       Impact factor: 2.626

Review 2.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

3.  Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients.

Authors:  R W Holl; D Kunze; H Etzrodt; W Teller; E Heinze
Journal:  Eur J Pediatr       Date:  1994-01       Impact factor: 3.183

Review 4.  Fracture risk and bone mineral density in Turner syndrome.

Authors:  Vladimir K Bakalov; Carolyn A Bondy
Journal:  Rev Endocr Metab Disord       Date:  2008-04-15       Impact factor: 6.514

5.  Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture.

Authors:  Teddy G Goetz; Ramanaiah Mamillapalli; Maureen J Devlin; Amy E Robbins; Masoumeh Majidi-Zolbin; Hugh S Taylor
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-08-01       Impact factor: 4.310

Review 6.  Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies.

Authors:  Maria Felicia Faienza; Annamaria Ventura; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2016-04-26       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.